Suppression of AKT expression by miR-153 produced anti-tumor activity in lung cancer

International Journal of Cancer

Volumn 136, Issue 6, 2015, Pages 1333-1340

  Yuan, Ye ^a   Du, Weijie ^a   Wang, Ying ^a   Xu, Chaoqian ^a   Wang, Jinghao ^a   Zhang, Yang ^a   Wang, Huimin ^a   Ju, Jiaming ^a   Zhao, Liang ^a   Wang, Zhiguo ^a   Lu, Yanjie ^a   Cai, Benzhi ^a   Pan, Zhenwei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

AKT; Lung cancer; miR 153; Proliferation

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 153; PROTEIN KINASE B; UNCLASSIFIED DRUG; MIRN153 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; AKT1 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; DRUG TARGETING; EMBRYO; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALE; MOUSE; NONHUMAN; PLASMID; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICRORNAS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84922214693     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29103     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Farazi TA, Hoell JI, Morozov P, et al. Micro-RNAs in human cancer. Adv Exp Med Biol 2013;774:1-20.
3. Enfield KS, Pikor LA, Martinez VD, et al. Mechanistic roles of noncoding RNAs in lung cancer biology and their clinical implications. Genet Res Int 2012;2012:737416.
4. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6.
5. Wang R, Wang ZX, Yang JS, et al. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 2011;30:2644-58.
6. Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010;18:282-93.
7. Garofalo M, Di Leva G, Romano G, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009;16:498-509.
8. Zhao S, Deng Y, Liu Y, et al. MicroRNA-153 is tumor suppressive in glioblastoma stem cells. Mol Biol Rep 2013;40:2789-98.
9. Xu Q, Sun Q, Zhang J, et al. Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer. Carcinogenesis 2013;34:539-49.
10. 3-induced apoptosis. Med Oncol 2012;29:243-7.
11. Wu Z, He B, He J, et al. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. Prostate 2013;73:596-604.
12. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628-32.
13. Takahashi Y, Forrest AR, Maeno E, et al. MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One 2009;4:e6677.
14. Xu J, Liao X, Wong C. Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. Int J Cancer 2010;126:1029-35.
15. Zhang L, Pickard K, Jenei V, et al. miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res 2013;73:6435-47.
16. Hutchinson J, Jin J, Cardiff RD, et al. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 2001;21:2203-12.
17. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455-64.
18. David O, Jett J, LeBeau H, et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004;10:6865-71.
19. Tang JM, He QY, Guo RX, et al. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006;51:181-91.
20. Lee HY, Oh SH, Suh YA, et al. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res 2005;11:6065-74.
21. Switzer CH, Ridnour LA, Cheng RY, et al. Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. Oncogene 2009;28:3837-46.
22. Vinall RL, Ripoll AZ, Wang S, et al. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer 2012;130:2526-38.
23. Cui SY, Wang R, Chen LB. MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers. J Cell Mol Med 2012;17:1207-17.
24. Du L, Subauste MC, DeSevo C, et al. miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One 2012;7:e39167.